Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a chinese population and association with attenuated response to aspirin

Pharmacogenomics

Volumn 8, Issue 6, 2007, Pages 577-586

  Li, Qing ^a   Chen, Bi Lian ^a   Ozmedir, Vural ^b   Ji, Wei ^a   Mao, Yan Mei ^a   Wang, Lian Ci ^a   Lei, Hei Ping ^a   Fan, Lan ^a   Zhang, Wei ^a   Liu, Jie ^a   Zhou, Hong Hao ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Allele frequency; Asians; Aspirin resistance; Association; COX1; Genotype phenotype; GPIIIa; Interethnic differences; P2Y1; Platelet aggression

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CYCLOOXYGENASE 1; GLYCOPROTEIN IIIA; PURINE P2Y1 RECEPTOR;

ADULT; ARTICLE; CAUCASIAN; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG RESEARCH; DRUG RESPONSE; ETHNIC DIFFERENCE; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; MALE; NORMAL HUMAN; PATIENT COMPLIANCE; PHARMACODYNAMICS; PHARMACOGENETICS; POPULATION RESEARCH; PROSPECTIVE STUDY; SAMPLE; STATISTICAL ANALYSIS; THROMBOCYTE; THROMBOCYTE AGGREGATION; VOLUNTEER;

ADULT; ASPIRIN; CYCLOOXYGENASE 1; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE FREQUENCY; HUMANS; INTEGRIN BETA3; MALE; PLATELET AGGREGATION; POLYMORPHISM, GENETIC; PROSPECTIVE STUDIES; RECEPTORS, PURINERGIC P2;

EID: 34250625249     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.8.6.577     Document Type: Article

References (42)

1. Jack DB: One hundred years of aspirin. Lancet 350, 437-439 (1997).
2. Larer M: Aspirin for primary prevention of coronary events. N. Engl. J. Med. 346, 1468-1474 (2002).
3. Mehta P: Aspirin in the prophylaxis of coronary artery disease. Curr. Opin. Cardiol. 17, 552-558 (2002)
4. Awtry EH, Loscalzo J: Aspirin. Circulation 101, 1206-1218 (2000).
5. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 231, 232-235 (1971).
6. Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38, 97-120 (1998).
7. Altman R, Luciardi HL, Muntaner J, Herrera RN: The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? Thrombosis J. 2, 1 (2004).
8. Patrignani P, Filabozzi P, Patrono C: Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J. Clin. Invest. 69, 1366-1372 (1982).
9. Mason PJ, Freedman JE, Jacobs AK: Aspirin resistance: current concepts. Rev. Cardiovasc. Med. 5, 156-163 (2004).
10. Helgason CM, Bolin KM, Hoff JA et al.: Development of aspirin resistance in persons with previous ischemic stroke. Stroke 25, 2331-2336 (1994)
11. Pappas JM, Westengard JC, Bull BS: Population variability in the effect of aspirin on platelet function. Implications for clinical trials and therapy. Arch. Pathol. Lab. Med. 118, 801-804 (1994).
12. Grotemeyer KH: Effects of acetylsalicylic acid in stroke patients. Evidence of nonresponders in a subpopulation of treated patients. Thromb. Res. 63, 587-593 (1991).
13. Grotemeyer KH, Scharafinski HW, Husstedt IW: Two-year follow-up of aspirin responder and aspirin non responder. A pilot study including 180 poststroke patients. Thromb. Res. 71, 397-403 (1993).
14. Helgason CM, Tortorice KL, Winkler SR et al.: Aspirin response and failure in cerebral infarction. Stroke 24, 345-350 (1993).
15. Gum PA, Kottke-Marchant K, Poggio ED et al.: Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol. 88, 230-235 (2001).
16. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi QL, Yusuf S: Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 105, 1650-1655 (2002).
17. Halushka MK, Halushka PV: Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation 105, 1620-1622 (2002).
18. Halushka MK, Walker LP, Halushka PV: Genetic variation in cyclooxygenase I: Effects on response to aspirin. Clin. Pharmacol. Ther. 73, 122-130 (2003).
19. Jin J, Daniel JL, Kunapuli SP: Molecular basis for ADP-induced platelet activation. II: the P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J. Biol. Chem. 273, 2030-2034 (1998).
20. Hollopeter G, Jantzen HM, Vincent D et al.: Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 409, 202-207 (2001).
21. Jefferson BK, Foster JH, McCarthy JJ et al.: Aspirin resistance and a single gene. Am. J. Cardiol. 95, 805-808 (2005).
22. Hetherington SL, Singh RK, Lodwick D, Thompson JR, Goodall AH, Samani NJ: Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. Arterioscler. Thromb. Vasc. Biol. 25, 252-257 (2005).
23. Lefkovits J, Plow EF, Topol EJ: Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N. Engl. J. Med. 332, 1553-1559 (1995).
24. Cooke GE, Bray PF, Hamlington JD, Pham DM, Goldschmidt-Clermont PJ: PLA2 polymorphism and efficacy of aspirin. Lancet 351, 1253 (1998).
25. Undas A, Sanak M, Musial J, Szczeklik A: Platelet glycoprotein IIIa polymorphism, aspirin, and thrombin generation. Lancet 353, 982-983 (1999).
26. Michelson AD, Furman MI, Goldschmidt-Clermont P et al.: Platelet GP IIIa Pl(A) polymorphisms display different sensitivities to agonists. Circulation 101, 1013-1018 (2000).
27. Andrioli G, Minuz P, Solero P et al.: Defective platelet response to arachidonic acid and thromboxane A2 in subjects with PLA2 polymorphism of β3 subunit glycoprotein IIIa. Br. J. Haematol. 10, 911-918 (2000).
28. Shi YY, He L: SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 15, 97-98 (2005).
29. Park S, Park HY, Park C et al.: Association of the gene polymorphisms of platelet glycoprotein Ia and IIb/IIIa with myocardial infarction and extent of coronary artery disease in the Korean population. Yonsei. Med. J. 45, 428-434 (2004).
30. Chen CH, Lo YK, Ke D et al.: Platelet glycoprotein Ia C807T, Ib C3550T, and IIIa Pl(A1/A2) polymorphisms and ischemic stroke in young Taiwanese. J. Neurol. Sci. 227, 1-5 (2004).
31. Macchi L, Christiaens L, Brabant S et al.: Resistance in vitro to low-dose aspirin is associated with platelet PlA1 (GP IIIa) polymorphism but not with C807T(GP Ia/IIa) and C-5T Kozak (GP Ibα) polymorphisms. J. Am. Coll. Cardiol. 42, 1115-1119 (2003).
32. Pamukcu B, Oflaz H, Nisanci Y: The role of platelet glycoprotein IIIa polymorphism in the high prevalence of in vitro aspirin resistance in patients with intracoronary stent restenosis. Am. Heart J. 149, 675-680 (2005).
33. Ozdemir V, Williams-Jones B, Glatt SJ et al.: Shifting emphasis from pharmacogenomics to theragnostics. Nat. Biotechnol. 24, 942-946 (2006).
34. Cambria-Kiely JA, Gandhi PJ: Aspirin resistance and genetic polymorphisms. J. Thromb. Thrombolysis 14, 51-58 (2002).
35. Terres W, Weber K, Kupper W, Bleifeld W: Age, cardiovascular risk factors and coronary heart disease as determinants of platelet function in men. A multivariate approach. Thromb. Res. 62, 649-661 (1991).
36. Cox D, Fitzgerald D: Monitoring antiplatelet therapy in platelets in thrombotic and non-thrombotic disorders. In: Pathophysiology, Pharmacology and Therapeutics. Gresele P, Page CP, Fuster V, Vermylen J (Eds.), Cambridge University Press, Cambridge, UK, 471-484 (2002).
37. Burke J, Kraft WK, Greenberg HE et al.: Relationship of arachidonic acid concentration to cyclooxygenase-dependent human platelet aggregation. J. Clin. Pharmacol. 43, 983-989 (2003).
38. Lim J, Lal S, Ng KC, Ng KS, Saha N, Heng CK: Variation of the platelet glycoprotein IIIa PI(A1/A2) allele frequencies in the three ethnic groups of Singapore. Int. J. Cardiol. 90, 269-273 (2003).
39. Mikkelsson J, Perola M, Penttila A, Goldschmidt-Clermont PJ, Karhunen PJ: The GPIIIa (β3 integrin) PlA polymorphism in the early development of coronary atherosclerosis. Atherosclerosis 154, 721-727 (2001).
40. Ozdemir V, Williams-Jones B, Cooper DM, Someya T, Godard B: Mapping translational research in personalized therapeutics: from molecular markers to health policy. Pharmacogenomics 8(2), 177-185 (2007).
41. Ozdemir V, Kalow W, Tothfalusi L, Bertilsson L, Endrenyi L, Graham JE: Multigenic control of drug response and regulatory decision-making in pharmacogenomics: The need for an upper-bound estimate of genetic contributions. Curr. Pharmacogenomics 3, 53-71 (2005).
42. Kirchheiner J, Fuhr U, Brockmoller J: Pharmacogenetics-based therapeutic recommendations - ready for clinical practice? Nat. Rev. Drug Discov. 4(8), 639-647 (2005).